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Aims: We conducted a meta-analysis of serious adverse events (dementia, macro- and
micro-vascular events, falls and fractures, and death) associated with hypoglycemia in
older patients treated with glucose lowering drugs.
Materials and Methods: Meta-analysis of studies reporting on hypoglycemia and
adverse events. The search included studies from two previously published systematic
reviews, and an updated search of MEDLINE and EMBASE from April 2014 to November
2019. We assessed study validity based on ascertainment of hypoglycemia, adverse
events and adjustment for confounders, and conducted a random effects meta-analyses,
assessing heterogeneity using the I2 statistic.
Results: We included 44 studies involving 2,507,434 participants. Most of the studies
used adjusted analysis for confounders and hypoglycaemic events were typically
identified based on healthcare databases (severe events). Hypoglycemia was
associated with increased likelihood of death in a meta-analysis of eighteen studies,
pooled OR 2.02 (95% Confidence Interval 1.75–2.32). Studies assessing mortality signal a
time-response relationship with a higher risk of adverse events occurring within the first 90
days after hypoglycemia. Our meta-analysis of nine studies demonstrated that
hypoglycaemic episodes were associated with dementia – pooled OR 1.50 (95% CI
1.29–1.74). Our meta-analysis of nineteen studies demonstrated associations between
hypoglycaemia and macrovascular complications, pooled OR 1.81 (95% CI 1.70–1.94),
and microvascular complications (two studies) pooled OR 1.77 (95% CI 1.49–2.10). There
is also an association between hypoglycemia and cardiovascular death (six studies) –
pooled OR 2.11 (95% CI 1.55 to 2.87). Similarly, our meta-analysis of six studies
demonstrated an association between hypoglycemia and falls and fractures, pooled OR
1.78 (95% CI 1.44–2.21) and 1.68 (95% CI 1.37–2.07) respectively.
Conclusion: This meta-analysis confirms previously reported concerns of serious harm
following hypoglycemia, especially in the immediate time period after a hypoglycaemic event.
Avoidance of hypoglycaemic episodes should be a priority in this vulnerable population.
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We have previously published two meta-analyses on adverse events
(dementia,macro- andmicro-vascular events, falls and fractures, and
death associated with hypoglycemia in older people treated with
glucose-lowering drugs (1, 2). However, since those publications in
2016, we are aware of many new studies [including the authors’ own
work (3)] on adverse events associated with hypoglycemia. Hence,
we have updated our meta-analyses and present a comprehensive
review of the up to date evidence regarding the association
between hypoglycemia and adverse events in older people.
Our first systematic review looked at the bi-directional
relationship between hypoglycemia and dementia (2). The key
findings of the meta-analyses were a 70% increased risk of
deterioration in cognition following hypoglycemia and conversely
a 60% increased risk of hypoglycemia in older people with
dementia. However, this review did not include other major
adverse events that may be associated with hypoglycemia. Hence,
our second systematic review which focused on vascular adverse
events, falls and fractures and all-cause mortality. We found a 1.5
times increased risk in macrovascular events (ischaemic strokes,
myocardial infarctions) and a doubling of risk in falls, fractures, and
all-cause mortality, but there was insufficient data on cardiovascular
death to enable meta-analysis (1). This second review also did not
find any studies that specifically looked at the effects of
hypoglycemia in older patients who also have dementia.
This updated search of the most recent evidence allows us to
access a far larger data set and perform meta-analyses of
additional cardiovascular outcomes and time-relationships that
we could not previously address due to insufficient data.
MATERIALS AND METHODS
We worked from the methods described in previously published
meta-analyses (1, 2).
Data Sources and Searches
The population we were interested in was older adults. The
intervention was ‘hypoglycemia’ and the comparator ‘no
hypoglycemia’. The outcomes of interest were cardiovascular
events, falls and fractures, death and dementia.
The searches we ran only included terms for the population
and the intervention, as the outcomes are too diverse and non-
specific for us to be confident that we would capture all the
relevant papers if we focused on particular outcomes. For instance,
myocardial infarction could be described under a multitude of
terms as acute coronary syndrome, STEMI or NSTEMI.
Three searches fed into this systematic review and
meta-analysis.
For both previously published reviews, we searched MEDLINE
and EMBASE for a ten-year period up to March 2015 with English
language restriction.
Bibliographies of included studies were checked for other
potentially suitable studies. We were notified through PubMed
automated updates of any new relevant studies.
The search strategy for the current review was conducted up
to November 2019 and can be found in Appendix 1.Frontiers in Endocrinology | www.frontiersin.org 2Study Selection
In our analysis, we included cohort studies (prospective and
retrospective), which examined the association between
hypoglycemia and serious adverse events in participants aged 55
years and older on glucose-lowering medications. We used an
arbitrary cut-off of 55 years because there is no internationally
accepted definition, and we aimed to be broad rather than too
restrictive.We treated post-hoc analyses of randomized controlled
trials as cohort studies, as the analysis is no longer on a
prospective randomized basis due to post-hoc classification of
patients (with and without hypoglycemia).
We excluded cross-sectional studies, because it would be
impossible to determine whether the intervention (hypoglycemia)
or outcome (adverse events) occurred first.
We included only full journal publications because abstracts
are limited in word count and cannot fully describe the statistical
models and confounding variables that are of key interest in non-
randomized studies.
Data Extraction and Quality Assessment
Two authors conducted study screening and data extraction
independently. Uncertainties and discrepancies were resolved
through discussion.
We used a standardized form to collect data on study design,
study year, geographical location, setting, selection criteria,
participants’ characteristics and outcome measures. We extracted
relative measures of effect such as odds ratios, risk ratios, and hazard
ratios for the outcomes of interest in the group with hypoglycemia
as compared to the controls (please refer to Tables 1 and 2). For the
sensitivity analysis of survival at different time-points we have
focussed only on studies that report hazard ratios.
The outcomes (adverse events) of interest were dementia, falls
and fractures, composite cardiovascular (macrovascular) and
microvascular events and all-cause mortality.
We independently assessed study validity by looking at how
hypoglycemia and serious adverse events were recorded and
whether adjustments were made for potential confounding factors.Data Synthesis and Analysis
We performed a random effects meta-analysis of the relative
effect measures using the generic inverse variance method
(Revman 5.3, Nordic Cochrane Centre, Kobenhavn). As adverse
events are rare, odds ratios and risk or hazard ratios will yield
similar estimates of relative effect, and we have pooled all of them
using a random effects model. The random effects method for
meta-analyses takes into account heterogeneity and estimates an
average effect, considering differences in intervention effects as
random, rather than the single true effect pooled estimate that
arises from the fixed effect model.
Heterogeneity was assessed by using the I2 statistic and visual
inspection of the forest plots.
We planned to construct a funnel plot if we had more than 10
studies in the meta-analysis (without evidence of statistical
heterogeneity - I2 <50%).
As this was a systematic literature review, ethics approval was
not required.March 2021 | Volume 12 | Article 571568
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Study ID Design Data source Number of
patients, setting, dates
How were the patients
selected for study
Diabetes definition & Patient Characteristics, age,












Lothian Diabetes Register Type 2 diabetes, mean age 68 years, male 51%
31% previous coronary heart event, 8.7% previous










77 clinical centres in
North America
RCT (ACCORD) in patients
with Type 2
Type 2 diabetes, mean age 62.2 years, male 62%. Had
either established cardiovascular disease or additional
cardiovascular risk factors. Exclusions: past severe
hypoglycaemia, BMI >45, serum creatinine >133




Cha et al. (6) Prospective
cohort




up until May 2015),
1260 participants, South
Korea
Vincent Type 2 Diabetes
Registry
Type 2 diabetes, mean age 55 years, female 59%
Exclusions: older than 75 years, mental health illness,
unable to undertake self-care, previous episodes of SH,
cognitive impairment, alcohol excess, malignancy, end-







Tokyo, Japan, Dec 2009-
Apr 2011
Outpatient diabetes clinic
attended for ≥one year.
>60 years
168 T2DM patients and 43 age-matched, non-diabetic
controls
Exclusion: blindness, wheelchair/bedridden, end-stage

















and Assessment Service of
Korea (HIRAS)
Type 2 diabetes, mean age 68 years, 47% male, mean
diabetes duration 8 years
Exclusions: history of hypoglycaemia. cognitive













to 2005, 573 sites in 40
countries
ORIGIN trial Individuals with impaired fasting glucose, impaired
glucose tolerance or early type 2 diabetes who also had
additional cardiovascular risk factors
Mean age 66 years (SH), 63 years (non-SH), female 26%
(SH), 33% (non-SH), baseline MMSE >24














across the United States
VADT trial Type 2 diabetes, 97% male, median follow-up 5.6 years,
inadequate response to maximal doses of oral agents or
insulin therapy.
Mean age 60.4 years
Exclusions: HbA1c <7.5%, cardiovascular event during
previous 6 months, advanced congestive heart failure,
severe angina, life expectancy <7 years, BMI>40, serum
creatinine level >141 micromol/L, alanine













RCT (VADT) Mean age 60.3 years
97% male
T2DM
Exclusions: recent cardiovascular event, serious co-
















Patients with type 2 diabetes making first pharmacy
claim for basal insulin, included if previously on GLP-1
analogs/oral hypoglycaemic agentes and had at least 2
years of Medicare Advantage coverage.
Mean age 72 years.















2006 and 20 April 2008
314 centres in 12
countries
CREDIT study inclusion criteria: Type 2 diabetes, age >40 years, started
insulin >1 month and <6 months prior to study entry and
who had HbA1c measurement within 3 months prior to
starting insulin.
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Study ID Design Data source Number of
patients, setting, dates
How were the patients
selected for study
Diabetes definition & Patient Characteristics, age,












Centre Co Ltd database
Inclusion criteria: Type 2 diabetes or unspecified
diabetes, prescription of glucose-lowering agent,
observation for a continuous period of at least.6 months
from January 2005 to July 2014.
Mean age 56 years.
Exclusions: <18 years or >75 years, type 1 diabetes,











Seniors with newly diagnosed diabetes and matched
comparison cohort without diabetes aged 66-105
between 1 April 1995 to 31 March 2007. Median age 73
years.
Followed until 31 March 2012 for a new diagnosis of
dementia











EXAMINE trial Type 2 diabetes requiring anti-hyperglycaemic
medications with a baseline HbA1c of 48-97 mmol/mol










hypoglycaemia group n =





Patients aged 20 years and older with T2DM –ICD-9
codes plus three OP visits or more with a diabetes
diagnosis code over a 1-year period or at least 1
hospitalization with diagnostic code for T2DM.
Patients with one HE constituted the hypoglycaemic
group. Excluded: undetermined hypoglycaemia,
neonatal/infant hypoglycaemia. Mean age 67.8 years;
male 48.4%
Control group: patient with T2DM and no HE were
matched 4:1 to hypoglycaemic group, based on age and
diabetes duration.









Enrolled in National Health
Insurance
>60 years, newly diagnosed T2DM (with ≥3 outpatient
claims ICD-9-CM code 250). Mean age 65.2 years.












Type 2 diabetes, mean age 70 years, male 43%
Controls were frequency matched on age within 5 years,
on gender and on duration of diabetes at a ratio of 1:2
Exclusions: pathological fractures, transportation
accident before the index date








US, 30 September 2006







Age>65 years with T2DM (≥1 claim with diagnosis code)
and ≥2 prescriptions claims for antidiabetic drugs
Continuous enrolment and pharmacy benefits
throughout 24-months

















Mean age 75, 52% male, T2DM (≥1 claim with diagnosis
code) and ≥2 prescriptions claims for antidiabetic drugs
Continuous enrolment and pharmacy benefits













matched with 21,613 non-
hypoglycaemia patients
Type 2 diabetes
Randomly matched to controls 1:1 by age, gender















All insulin users, age >30 years.
T2DM sample mean age 63, male 56%
Exclusion: patient without linkage to HES, pre-index
period ≤180 days, hypoglycaemia before index, no
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Study ID Design Data source Number of
patients, setting, dates
How were the patients
selected for study
Diabetes definition & Patient Characteristics, age,






















Patients with t2DM and prescribed oral hypoglycaemic
agents or insulin. Index date 1 January 2002. Mean age
76 years.
Exclusions: T1DM, dementia, dementia medication















Type 2 diabetes with and without SH in the 12 months
before enrolment
Median age 58 years.















(4th study visit in 1996-
1998 Is baseline for this
analysis)
US
ARIC study Participants with diabetes identified by self-report of a
physician diagnosis or use of glucose lowering
medication at 4th ARIC study visit.
Mean age 64 years.
Exclusions: 4 participants who did not identify as black
or white and six black participants form the Minnesota or
Maryland study site. Excluded those missing covariates.
Cause of death was missing for 29 participants, and they























selected from visit 5
(2011–2013) with 2001,





baseline at visit 4 (1996–
1998), with follow-up to
end 2013
ARIC study Diagnosed diabetes by self-report of diagnosis or













Primary care Network Type 1 or type 2 diabetes patients without coronary
artery disease before 1 January 2006;
Follow-up until earliest incident of CAD, last clinic visit,
death or 30 June 2012.
Exposed: 1 or more hypoglycaemic events in 2000-
2005;
Unexpoosed: no reported hypoglycaemia before 1
January 2006
Mean age 60 years.
Exclusions: patients with CAD before 1 Jnauary 2006
Oral hypoglycaemic
agents, insulin






Type 2 diabetes (ICD9-CM)
no prior dementia
45% male Mean age 64
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Study ID Design Data source Number of
patients, setting, dates
How were the patients
selected for study
Diabetes definition & Patient Characteristics, age,
sex (or Selection of Cases and Controls)
Type of glucose
lowering agents







31049 enrolled in each of
three groups
Insurance database Type 1 and type 2 diabetes plus reference group without
diabetes. Diabetes patients divided into those with and
those without hypoglycaemia
Mean age in patients with diabetes and hypoglycaemia
63 years, 46% male
Exclusions: admissions to hospital with cancer or any
diagnoses of accident between 1997 to the date of first
clinic visit for diabetes in 2000 (=index date)
Follow-up; from index date to occurrence of first of date
of 1st hospitalization due to falls, date of attrition from
insurance or 31 December 2008.
Medications not








Network and the provincial
health ministry (Alberta
Health)
Outpatients age>66 years (mean 75) who had
administrative data for both serum creatinine and HbA1c














CPRD database Patients aged 65 or older with diabetes, defined as a first
ever prescription of any oral or injectable glucose-
lowering agent between April 1997 and March 2016.
Follow-up continued for up to five years from the
exposure, loss from database, death, or end of available
database linkage (HES 31 March 2016 and ONS 17 April












Medical records Type 1 and Type 2 diabetes, mean age 60.5 years, male
55%, history of hypoglycaemia established prior to index
clinical encounter












CPRD New diagnosis of type 2 diabetes from 2003-2012, >65
years
Exclusions: patients with dementia diagnosis in a year
prior to index date (=1st date of diabetes diagnosis or a
laboratory value indicating diabetes diagnosis), patients
















with IFG, IGT, newly
detected diabetes, or
established diabetes
50 years or older (mean age 63.5, 65% male)
with cardiovascular risk factors
60% had prior cardiovascular event, 80% had prior
diagnosis of diabetes, 6% had newly detected Type2
diabetes, 12% had impaired glucose tolerance or
impaired fasting glucose. Median baseline HbA1c 6.4%














Type 2 diabetes aged 18 and older, registered in general
practices contributing to THIN between 1 January 1995
to 1 May 2016
Mean age 67 years.
Follow-up: earliest of transfer date, death date, first
documentation of outcome (fracture) or study end date)
History of hypoglycaemia = exposed cohort
No history of hypoglycaemia = unexposed cohort.















to either insulin degludec
or insulin glargine
DEVOTE trial Type 2 diabetes with at least one oral or injectable
glucose-lowering agent with HbA1c >7.0% (53mmol/L)
or with >20 units/day basal insulin. Either had at least
one co-existing cardiovascular or renal condition and
were aged >50 years or had at least one of a list of pre-
specified cardiovascular risk factors and were aged >60
years.
NOT excluded if experienced SH prior to randomisation.








US, (1 January 2002 to
OptumInsight, medical
claims database
>65 years (mean 72.5 years) with T2DM
1:1 propensity matching score (Sulfonylurea v non-
SU
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Study ID Design Data source Number of
patients, setting, dates
How were the patients
selected for study
Diabetes definition & Patient Characteristics, age,
sex (or Selection of Cases and Controls)
Type of glucose
lowering agents




Exclusion criteria: drug supply <30 days, insulin use,
prior hip fracture, SU initiation among non-users or
discontinuation among users after the index date
Rathmann
et al. (38)
Retrospective 19184 DPP-4 and 31110
SU users (total: 50294)
Germany (1201 general
practices), April 2007 to
July 2010
Primary care data: Disease
Analyzer Database (IMS
HEALTH)
Type 2 diabetes with first time prescription (index date) of
either DPP-4 inhibitors or SU from
Continuous treatment in same practice
Mean age 64 (DPP-4) and 69 (SU)
Excluded: use of both SU and DPP-4 inhibitor; insulin








Claims database from self-
insured companies
T2DM who had filled ≥2 prescriptions for oral
hypoglycemic drugs
Mean age 60; Male 50%
Random sample without hypoglycaemia 5:1 ratio to
hypoglycaemic patients















trial designed to assess
CV safety of sitagliptin vs
placebo
TECOS trial Type 2 diabetes, pre-existing coronary, cardiovascular or
peripheral atherosclerotic disease, >50 years, baseline
HBA1c 6.5-8% (48-64mmol/L)
Mean age 65 years.
Exclusion: those on DPP4 inhibitor, GLP-1 agonist,
Rosiglitzone during the preceding three months, >2SH
episodes in the previous 12 months, eGFR <30 ml/min














No prior diagnoses of dementia, mild cognitive







enrolled in Health, Aging,
and Body Composition
Study. Excluded those
with evidence of possible
cognitive impairment at
study baseline





















Type 2 diabetes, mean age 63, male 96%
Excluded: patients with 1-year pre-index records of
hypoglycaemia, cardiovascular, and microvascular
















Mean age 76.5, Type 2 diabetes
Excluded: patients with T1DM, patients with 6-month












LEADER trial Type 2 diabetes; age 50 years or older and established
CV disease or chronic renal failure OR age >60 years
and risk factors for CV disease, HbA1c >7%
Randomized to liraglutide or placebo both in addition to
standard-of-care. Follow-up 3.5-5 years.
Mean age 65 years.
Exclusions: type 1 diabetes, use of GLP-1 agonist, DDP-
4 inhibitors, pramlitinide, or rapid-acting insulin, history of
MEN type 2 or medullary thyroid cancer and occurrence
of an acute coronary or cerebrovascular event.
Oral hypoglycaemic
agents, insulin
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Study ID Design Data source Number of
patients, setting, dates
How were the patients
selected for study
Diabetes definition & Patient Characteristics, age,









215 centres in 20
countries
June 2001 to March
2003
ADVANCE randomized
controlled trial of intensive
glucose lowering (between)
Type 2 diabetes, ≥55 yrs, diagnosis after the age of 30
and had a history of macrovascular or microvascular
disease or at least one other cardiovascular risk factor.
Mean age 66 years. Excluded if clear indication for long-




agent(s)Frontiers in Endocrinology | www.frontiersin.org 8 March 2021 | VolumeOR, Odds ratio; HR, Hazard ratio; 95% CI, 95% Confidence Interval; T2DM,Type 2 diabetes mellitus; HbA1C,glycated haemoglobin; CKD, chronic kidney disease; DPP-4,dipetidyl-
peptidase-4; SU, Sulfonylureas; MI, myocardial infarction; AF, atrial fibrillation; CVD, cardiovascular disease; HES, Hospital Episode Statistic; CPRD, Clinical Practice Research Datalink
database; TUG, Timed Up and Go Test; GDS-15,Geriatric Depression Scale; CCI, Charlson comorbidity index; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; SH, severe
hypoglycaemia; ACEi, angiotension-converting enzyme inhibitor; ARB, angiotension receptor blocker; TIA, transient ischemic attack; MMSE, Mini-Mental State Examination; eGFR,
estimated glomerular filtration rate.TABLE 2 | Study outcomes, results and risk of bias.
Study ID Method of diagnosing each type
of adverse event
Method of diagnosing or determining that
patients had hypoglycaemia
Statistical adjustments for




Primary outcomes were MI (fatal or
nonfatal), angina, TIA, stroke (fatal or
nonfatal). Composite macrovascular
disease outcome defined as one or
more episodes of MI, angina, TIA or
stroke. Coronary heart disease
defined by occurrence of MI or
angina. Cerebrovascular disease
defined by occurrence of stroke or
TIA.
Self-report questionnaire or via GP
questionnaire, WHO chest pain
questionnaire, ECG and hospital
discharge data linkage from





regression models adjusting for age,
sex, blood pressure, HbA1c, total
cholesterol, HDL cholesterol, BMI,
eGFR, duration of diabetes, smoking
status, diabetes treatment method,
medications, microalbuminuria
Macrovascular disease
events aOR 2.11 (1.06–
4.21);
Coronary heart disease
events aOR 2.44 (1.13–
5.26);
Cerebrovascular disease
events aOR 2.01 (.029–
3.61);
MI aOR 4.02 (1.54–
10.48);




Pre-specified primary outcome: non-
fatal MI or non-fatal stroke and
cardiovascular death
Pre-specified secondary outcome: all
cause mortality
Blinded independent adjudication of
outcomes
Investigators asked patients about
hypoglycaemic events at each visit. Patients
were given home glucose monitors:
-symptomatic severe hypoglycaemic event
requiring medical assistance (HMA); blood
glucose <2.8mmol/L or symptoms resolved
with treatment
-symptomatic severe hypoglycaemic event
requiring any assistance (HA)
Cox regression models (stepwise
procedure)
Confounders: baseline covariates,
age, gender, ethnicity, education,
BMI, alcohol, smoking, cardiovascular
disease, diabetes duration, diabetic
complications, cardiovascular risk





intensive arm aHR 1.41
(1.03, 1.93)
standard care arm aHR
2.30 (1.46, 3.65)
Cha et al. (6) Primary outcome: death from any
cause or cardiovascular death
(deaths resulting from acute MI,
sudden cardiac death, death due to
heart failure, other CV causes)
CVD based on review of medical
records and diagnosis confirmed by
cardiologist, neurologist or
neurosurgeon.
Causes of death determined from
death certificates, clinical records
and hospital records
SH–hypoglycaemic episodes requiring the
assistance of medical care in an emergency
department or hospitalization. Patients were
asked if they had experienced SH; review of
medical records
Cox proportional hazards regression
with adjustments for: sex, age,
duration of diabetes, hypertension,
diabetic nephropathy, mean HbA1c,








questionnaire about frequency and
type of falls (defined as unexpected
event in which the person came to
rest on the ground, floor, lower level.
Complicated with a head injury or
fractures).
Professional interviewer with validated
questionnaire regarding hypoglycaemic
symptoms.
Severe: coma, convulsion, inability of self-
management and recovery from symptoms.
Mild: hypoglycaemic symptoms with
recovery within 10 minutes by self-
administered sugar or glucose.
Multiple regression analysis: age, sex,
cognitive impairment (MMSE <26),
TUG score, GDS-15 scores, Falls Risk




with presence of multiple
falls, and any fall OR 2.05
(0.93–4.535). Prevalence
of falls increased as the
frequency of
hypoglycaemia increased.
(Continued)12 | Article 571568
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Study ID Method of diagnosing each type
of adverse event
Method of diagnosing or determining that
patients had hypoglycaemia
Statistical adjustments for




Incident cases of dementia and
organic mental disorder were
identified form HIRAS claim
database (ICD-10 codes)
HIRAS claims database (ICD-10 codes) Cox proportional hazards regression
models adjusting for age, sex,
smoking status, alcohol status, BMI,
















defined either as reported dementia
(first occurrence of an affirmative
answer to a case report form
question) or a post-randomization
MMSE score of <24.
Sensitivity analysis conducted using
a more restrictive definition of
cognitive dysfunction (reported
dementia or two consecutive MMSE
scores <24 or last available MMSE
score <24)
Self-reported questionnaires. Nonsevere
hypoglycaemia defined as an event
associated with symptoms consistent with
hypoglycaemia and confirmed by a capillary
glucose reading of <54mg/dL (3mmol/L). SH
defined as a symptomatic events requiring
assistance of another person and there was
prompt recovery after oral carbohydrate, IV
glucose or glucagon and.or documented
self-measure or laboratory-measured plasma
glucose level of <36 mg/dL (2 mmol/L)
Cox proportional hazards regression
adjusting for baseline CVD, diabetes
status, allocation to glargine, allocation
to b-3 fatty acids, HbA1c as a time-
varying covarite, age.




























Primary outcome: time to first
occurrence of any one of a
composite of cardiovascular events
adjudicated by an end point
committee that was unaware of
study group assignments.
Cardiovascular events were
documented MI, stroke, death as a
result of cardiovascular causes, new
or worsening congestive cardiac
failure, surgical intervention for
cardiac, cerebrovascular, or
peripheral vascular disease,
inoperable coronary artery disease




SH defined as a self-reported episode of a
low blood glucose value accompanied by
confusion requiring assistance from another
person of loss of consciousness.
Cox proportional hazards regression
adjusting for treatment group, overall
cardiovascular risk (including factors
such as diabetes duration, HbA1c),
prior cardiovascular event, insulin use,
eGFR









2.40 (1.10 to 5.10)
Duckworth
et al. (11)
Cardiovascular event is pre-specified
composite: MI, stroke, CV death,
cardiac failure, vascular surgery,
inoperable coronary artery disease,
amputation for gangrene
Blinded independent adjudication of
outcomes
Routine trial monitoring Multivariate regression analysis
Confounders: prior cardiovascular
event, age, baseline insulin, ethnicity,
smoking status, HbA1c, lipids,











Medically attended hypoglycaemia events
identified from claims database–ICD-9 codes
Cox proportional hazards regression
for risk of hospitalization with
medically attended hypoglycaemia as
the time-varying covariate, adjusting
Medically attended
hypoglycaemia after
initiation of basal insulin
and risk of hospitalization
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Study ID Method of diagnosing each type
of adverse event
Method of diagnosing or determining that
patients had hypoglycaemia
Statistical adjustments for
confounding factors (if any)
Results
for demographic, comorbidity and
medication history factors
Three sensitivity analyses for mortality
modelling after hypoglycaemia: 1)
mortality risk amongst the population
with an MI, congestive heart failure,
peripheral vascular disease or stroke;
2) population with MI, CHF, PVD,
stroke, dementia or renal disease,3)
population without cancer
aHR 1.59 (1.53–1.65)
Hypoglycaemia and risk of
death aHR 1.50 (1.40–
1.60)
Sensitivity analyses
1) aHR 1.46 (1.34–1.58)




Primary outcomes: composite of
stroke of myocardial infarction or
cardiovascular-specific death;
relationship between reported
hypoglycaemic episodes and CV or
all-cause mortality
Cardiovascular events reported by
investigator in clinical report forms at
6-month intervals; supportive




Cardiovascular events: MI, stable
angina, severe unstable angina
leading to hospitalization, stroke,




Data were gathered in routine clinical
practice, and treating physicians were asked
to report updated participant data every 6
months
Cox proportional hazards regression
Time-to-event endpoints calculated
from date of insulin initiation and were
restricted to 54 months
Relationship between
reported hypoglycaemia
and CV death or all-cause
mortality
CV death and SH aHR
1.10 (0.34–3.57)






CVD defined as conditions during
hospitalization with both a diagnosis
of CVD (ischaemic heart disease,
stroke, peripheral artery disease) and
either a medical procedure
performed or a prescription to treat
CVD
Severe hypoglycaemia defined by ICD 10
code and prescription for either 50%
dextrose or glucagon infusion
Cox proportional hazards models to
evaluate association of SH with CVD
risk, adjusted for age, sex, duration of
diabetes, history of microvascular
disease, Charlson Co-morbidity index,
medications.









Dementia: defined based on one or
more hospitalisation records or two
outpatient physician billing claims
(within six months) listed relevant
ICD-9 claim
Healthcare administrative database records
of hospitalisation or emergency department
visits for hypoglycaemia
Cox proportional hazard modelling
Sensitivity Analyses to examine
whether detection bias could explain
elevated risk of dementia
Models were adjusted for baseline
income and co-morbidities, including
hypertension, chronic kidney disease
and vascular diseases of varying
aetiologies.
Cumulative incidence functions were






of dementia aHR 1.73
(1.62–1.84) based on





Primary endpoint in EXAMINE trial:
composite of death from
cardiovascular causes, nonfatal MI
or non-fatal stroke. Principal
secondary safety endpoint was
primary composite end point with
addition of urgent revascularization
due to unstable angina within 24
hours after hospital admission.
Exploratory endpoints included
death from cardiovascular causes
and death from any cause.
Assessed at study visits at 1, 3, 6, 9 and 12
months post-randomization during the first
year of the study and every 4 months during
subsequent years of participation.
Hypoglycaemic events characterized by local
investigators according to their intensity (mild
to severe) and seriousness (hospitalization or
ED management)
Cox proportional hazards models with
adjustments for age, sex, treatment,
HbA1c, glycaemic medication and
stratified by screening renal function
and geographic region
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Study ID Method of diagnosing each type
of adverse event
Method of diagnosing or determining that
patients had hypoglycaemia
Statistical adjustments for
confounding factors (if any)
Results
Independent central adjudication
committee adjudicated all suspected
primary end-point events and other





arrhythmia requiring hospital visit,
including VT, VF or sudden cardiac
arrest (SCA)–all ICD-9 codes
ICD-9 codes Cox Proportional Hazard Regression
Models with adjustments for age,
gender, AF, sinus node disease,
premature ventricular contractions,
stroke HTN, hyperlipidaemia, coronary
artery disease, COPD, heart failure,
VHD, PVD, CKD, ACEi, ARB, beta-
blockers, aspirin, clopidogrel, warfarin,






Cancer, stroke, coronary heart
disease and cardiovascular disease
identified from hospital claims
dataset, ICD-9-CM codes
Death status ascertained according
to discharge reasons with death or
critically ill at discharge, or if
insurance cover stopped due to
death.
Hospital claims dataset for severe
hypoglycaemia
Outpatient claims dataset for mild
hypoglycaemia
ICD-9-CM codes
Propensity score, Cox proportional
hazard model, Kaplan-Meier
Variables in propensity score
matching: age, sex, diabetes duration,
hypertension, heart disease, renal and
liver disease, cancer, mental disease,
socio-economic status, treatment
adherence.
HR 2.09 (1.63, 2.67) for
cardiovascular diseases,
HR 2.51 (2.00, 3.16) for
all-cause hospitalisation,




Primary outcome: hip fracture after
SH
Insurance claims ICD-9
Index date for SH was first date of the
development of hospitalized or ED
hypoglycaemic visit
Insurance claims ICD-9
Cox proportional hazards regression
models adjusted for sex, ESRD,
COPD, epilepsy, CAD, stroke,
dementia, Parkinsons, osteoporosis,
retinopathy, neuropathy, alcohol
misuse, TZD, estrogen, acarbose,




Risk of hip fracture higher





coronary artery bypass graft,
revascularisation, percutaneous
coronary intervention –≥one inpatient
or outpatient claim ICD-9-CM code
Acute MI, incident unstable
angina–≥1 inpatient claim with an
ICD-9-CM code
≥1 outpatient claim with ICD-9-CM diagnosis
code for hypoglycaemia (hypoglycaemic
events were allowed to occur at any time
during the evaluation period, including after
acute cardiovascular events)
Multiple logistic regression and
backwards stepwise selection
Adjusted for age, sex, geography,
insurance type, comorbidity scores,
cardiovascular risk and prior events,
diabetes complications, total baseline
medical expenditures.
OR 1.79 (1.69, 1.89) for
acute cardiovascular
events




Emergency department claim with
ICD-9-CM diagnosis code
≥1 outpatient claim with ICD-9-CM diagnosis
code for hypoglycaemia (hypoglycaemic
events allowed to occur at any time during




baseline medications, CCI, medical
encounters for diabetes, total baseline
medical expenditures, number of
medical codes
aOR for fall-related




Fall-related events defined as ICD-9-
CM codes 800.x-995.x, with a fall
being the external cause defined as
ICD-9-CM E-codes E880-E888
which were recorded within +/-2
days of each other in any order.
Composite fall events (e.g. fall with
head injury or fracture) identified
based on two or more claims codes
occurring within 2 days.
Admin claim data
ICD-9-CM codes 250.8, 251.0, 251.1 and
251.2
Logistic regression analysis
Patients matched on age and gender;
statistical adjustment on CCI
Risk of fall-related events





Cardiovascular event defined as a
composite of MI, stroke or
cardiovascular death (cause of death
Data on hypoglycaemic episodes were
obtained from HES via ICD-10 codes
9E16.0, E16.2)
Mutivariate Cox regression models
Covariates: age, sex, smoking status,
geographical region, history of
All-cause mortality for
T2DM: HR 1.94 (1.52,
2.47) and 2.39 (2.13,
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Study ID Method of diagnosing each type
of adverse event
Method of diagnosing or determining that
patients had hypoglycaemia
Statistical adjustments for
confounding factors (if any)
Results
obtained through linkage to Office
for National Statistics).
cardiovascular events before index
date, use of oral antidiabetic
medications, Charlson comorbidity
index, BMI, HbA1c
2.67) for those with and
without a history of CVD
Cardiovascular events for
T2DM: HR 1.70 (1.09,
2.64) and 1.50 (1.19,
1.88) for those with and
without a history of CVD
Kim et al.
(24)
Primary outcome: first diagnosis of
all-cause dementia–ICD-10 codes.
Secondary outcome: first diagnosis
of Alzheimer’s dementia or Vascular
dementia– ICD-10 codes.
ICD-10 codes Propensity-Score matched analysis;
confounding variables set as: age,
gender, socioeconomic status (at
index date), diagnoses (1 yr before
index date) (hypertension,
dyslipidaemia, end-stage renall
disease, malignancy, asthma, COPD,
connective tissue disease, AF, heart
failure, osteoporosis, cerebrovascular
disease, microvascular complications
of diabetes), medication use, obesity,
alcohol use.





All clinical outcomes ascertained
though Hospital Authority Central
Computer Management System,
which records diagnoses of all
hospital discharges, including
morality based on ICD-9 codes.
Mortality data cross-checked with
Hong Kong Death Registry. Cause
of death was defined by the principal
discharge diagnosis.
SH defined as one or more hospitalizations
for hypoglycaemia in the 12 months before
enrolment or during the follow-up period
from enrolment to death or 31 January 2009
Cox proportional hazards regression
models with adjustments for age, sex,
BMI, smoking satus, alcohol use,
LDL-C, HDL-C, systolic BP, HbA1c,
duration of diabetes, urinary albumin
to creatinine ratio, prior CVD, prior
cancer, medications at enrolment.
Hazard ratios of severe
hypoglycaemia for the risk
of all-cause death in







An expert committee adjudicated
all coronary heart disease and stroke
events. Adjudication for heart failure
began in 2005; all heart failure
events before 2005 were based on
hospitalization with a primary
position ICD-9 code. Incident atrial
fibrillation was based on
hospitalizations with ICD-9 codes for
atrial fibrillation or atrial flutter.
Mortality was assessed via proxy,
coroner reports, and the National
Death Index through 2013. Cause-
specific mortality was classified by
the underlying cause of death listed
on the death certificate.
Severe hypoglycemic events were identified
from hospitalizations, emergency department
visits, and ambulance calls with a validated
algorithm, using ICD-9 codes in the primary
position through 31 December 2013.
Hospitalization records were available from
ARIC surveillance of local hospitals. Linked
Medicare claims for hospitalizations,
emergency
department visits, and ambulance use were
available for participants enrolled in Medicare
fee-for-service part B.
Cox proportional hazards regression
models adjusting for age, sex race-
centre, diabetes medication use,
duration of diabetes, tertiles of
fructosamine, low eGFR, albumin-urea





and CV events and all-
cause mortality (Model 3)
Coronary heart disease
aHR 2.02 (1.27–3.20)







Assessment of cognitive status
(normal, mild cognitive impairment
or dementia) was based on available
cognitive test scores from visits 2
(1990–1992), 4 (1996–1998) and 5
(2011–2013), the Clinical Dementia
Rating (CDR), based on interviews
with participants and informants, the
Modified Telephone Interview for
Cognitive Status (TICS),
hospitalisation records and death
certificates.
Diagnoses were standardised using
an algorithm, with review by a panel
of experts, who overrode the
algorithm if indicated by their clinical
judgement.
Severe hypoglycaemic episodes were
identified from hospitalisations, emergency
department visits and ambulance calls by a
widely used algorithm that employs
primary position ICD-9 codes
Multinomial logistic
regression to compare the odds of
having mild cognitive
impairment or dementia by history of
severe hypoglycaemia
For the prospective incident dementia
analysis, we used a
Cox regression model for the
outcome of incident dementia,
with severe hypoglycaemia as a time-
varying exposure







at visit 4 in the
prospective incident
dementia analysis
Model 4 aHR 2.28 (1.58–
3.29)
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Method of diagnosing or determining that
patients had hypoglycaemia
Statistical adjustments for
confounding factors (if any)
Results
For the analysis of incident dementia,
a date of dementia diagnosis was
assigned as the date of
hospitalisation with a dementia ICD-
9 code or, if no
hospitalisation with dementia
occurred, the first date of detection
via the TICS or CDR, or visit 5.
Leong et al.
(28)
Electronic health record repository,
including outpatients, emergency
department and inpatient visits. iCD-
9 code-cased algorithm
Electronic health record repository, including
outpatients, emergency department and
inpatient visits.
Hypoglycaemia defined as hypoglycaemia
brought to medical attention. ICD-9 code-
based algorithm
Three Cox models for incident CAD
constructed, Model 3 fully adjusted
adjusting for sex, age, educational
attainment, CAD risk factors, insulin,
oral hypoglycaemics, total medication
count, retinopathy, neuropathy, renal
failure, eGFR, LDL < HDL, cancer,
dementia, dysrhythmias,
hospitalizations, weight loss within a
year, HbA1c measurements per year.
Hypoglcyaemia and
associated with CAD risk
aHR 1.90 (1.09–3.31)









Lin et al. (29) Dementia: ICD9-CM
Method of diagnosing not stated
ICD9-CM
Method of diagnosing not stated













Lu et al. (30) Falls needing admission to hospital–
fall-related diagnosis code in
discharge diagnosis during the
follow-up (ICD-9 codes). Unable to
distinguish between the falls
occurring before or during
hospitalization.
SH defined as presence of ICD-9 codes in




Large number of deaths during follow-
up: mortality as competing risk
Fine & Gray competing risks model
Sequential construction of multivariate
regression. Adjustments for age, sex,
type of diabetes, geographic area,
urbanization status, obesity, mental
health problems, neurological,
cardiovascular, endocrine, renal,
ophthalmic disorders epilepsy, stroke,
substance abuse












Primary outcome: all-cause mortality




Mortality and dates of hospitalisation
determined by linkage to provincial
health ministry databases.
Defined severe hypoglycaemia by the
presence of any inpatient discharge
diagnosis of hypoglycaemia (ICD-10 code
E15 or E16)
Multivariable Cox proportional hazard
methods
Adjusted for age, sex, socioeconomic
status (based on individual health
insurance premium level and median
neighbourhood income), index eGFR,
prevalent hypoglycaemia, co-






aHR 2.46 (2.17, 2.80)
Mattishent
et al. (3)
Outcomes were falls, fractures,
cardiovascular events (myocardial
infarction, ischemic stroke) and all-
cause mortality. Data obtained from
CPRD using Read codes and HES
with ICD codes
First hypoglycaemic episode recorded on the
primary (CPRD) or secondary (HES)
healthcare database from April 1997
onwards following initiation of a glucose-
lowering agent. Data on hypoglycaemic
episodes were obtained from CPRD using
Read codes and HES with ICD codes
Cox proportional hazard regression
models with adjustments for










aHR 2.00 (95% CI 1.61 to
2.48)
Mortality - aHR 2.36 (95%
CI 2.09–2.67)
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Ascertainment of mortality from
medical records and social security
death index
Investigator asked patients about
hypoglycaemic events
-mild hypoglycaemia: symptoms consistent
with hypoglycaemia not requiring any
assistance
-severe hypoglycaemia: similar symptoms
requiring external assistance
Logistic regression
Confounders: age, gender, type of
diabetes and duration, CCI, HbA1c






Outcome variable was time to
dementia–defined by diagnosis
codes from electronic medical
records.
Hypoglycaemia defined based on previously
defined algorithm for CPRD data. Modelled
as time-dependent variable. Read and Med
codes
Fine and Gray’s competing risk
model–extension of Cox model to
competing risk data by considering
subdistribution hazards.
Adjustments for: age, sex, HbA1c,
alcohol use, smoking status, diabetes
treatment, co-morbidities associated
with dementia.
Follow-up from 1st date of diabetes
diagnosis until they developed
dementia–censored at earliest of:









-Composite of cardiovascular death
(any death for which no non-
cardiovascular cause could be
identified), non-fatal MI (based on
clinical presentation, elevated
cardiac markers, and/or new
electrocardiographic changes), or
stroke (based on clinical
presentation and imaging)
-Mortality
Blinded independent adjudication of
outcomes
Participants recorded hypoglycaemic events
with glucose meters and diaries.
Investigators asked patients about
hypoglycaemic events at each study visit.
Non-severe hypoglycaemia: relevant
symptoms confirmed by glucose reading
<3mmol/L.
-severe hypoglycaemia: symptomatic
hypoglycaemia requiring assistance of
another person with (i) prompt recovery after
oral carbohydrate and/or (ii) documented
plasma glucose level <2mmol/L
Propensity score matching, as well as
Cox regression models addressing
potential confounders: age, gender,
ethnicity, education, prior
cardiovascular events, hypertension,
depression, current smoking, alcohol
intake, albumin/creatinine ratio >30
mg/g, diabetes and cardiovascular
drugs, BMI, waist-hip ratio, HbA1c,
fasting plasma glucose, lipids, serum
creatinine, mini-mental status, prior
diabetes mellitus
In those with severe
hypoglycaemia HR 1.58
(1.24, 2.02) for composite
event.
HR 1.71 (1.27, 2.30) for
cardiovascular death.




Primary outcome: any fracture;
secondary outcome: fragility fracture
Read codes obtained from database
Read codes obtained from database Incidence of outcome of interest was
compared between exposed and
unexposed group. Incidence Rate
Ratios derived using Poisson
regression adjusting for covariates:
age, sex, BMI, Townsend deprivation













(cardiovascular death, non-fatal MI,
non-fatal stroke)
Adjudication-confirmed SH was pre-
specified, multiplicity-adjusted secondary
outcome as defined by ADA as an episode
requiring the assistance of another person to
actively administer carbohydrates or
glucagon, or to take other corrective action.
Cox regression models
Adjustments for age, sex, HbA1c,
BMI, diabetes duration, insulin,
hepatic impairment, renal status,
cardiovascular risk group
Risk of MACE for
individuals who had vs
those who had not
experienced SH aHR 1.38
(0.96–1.96)
All-cause mortality aHR
2.51 (1.79 to 3.50)
Rajpathak
et al. (37)
Hip fracture defined as an ICD-9
code 820.xx
ICD-9 codes based on validated algorithm Multivariable logistic regression based
on propensity score as well as
adjustment for confounders:: age,
sex, Medicare cover, region, coronary
heart disease, stroke, osteoporosis,
dementia, CKD
aOR 2.42 (1.35, 4.34) for






determined based on primary care
diagnoses (ICD-10 codes) for
coronary heart disease (I20, I24 and
I25), MI (I21, I22, I23 and I25.2),
stroke (I63, I64, G45) and peripheral
ICD-10 codings (E16.0, E16.1, E16.2)
Frequency of patients with >1
hypoglycaemic event assessed 30, 90, 183,
365 and 730 days after index date
Adjusted for age, sex, type of practise
(diabetologist), practise region, health




HR 1.6 (1.1, 2.2) for
incident macrovascular
complications
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Inpatient and emergency department
claims based on ICD9-CM codes,
grouped into three codes: accidental
falls, motor vehicle accidents and
other accidents
ICD-9-CM codes for hypoglycaemia at any
place of service
Multivariable Cox-proportional hazard
models adjusted for age, gender,
demographics, co-morbidities of
diabetes, accident risk factors, CCI,
inpatient admissions, use of oral
hypoglycaemics.
Hypoglycaemia associated
with accidental falls aHR
1.36 (1.13, 1.65)




Primary 4-point composite MACE:
first confirmed event of CV death,
non-fatal MI, nonfatal stroke or
hospitalization for unstable angina
Secondary outcome: 3-point MACE
(Cv death.nonfatal MI/nonfatal
stroke), fatal/nonfatal MI, fatal/
nonfatal stroke, all-cause death,
hospitalization for heart failure
Adjudicated by independent clinical
events classification committee
At screening/enrollemnt, 4-month, 8-month
visits and then annual visits, the symptoms
and appropriate management of
hypoglycaemia were reviewed with
participants. SH episodes were recorded
systematically as prespecified events of
clinical interest: episodes in which a
participant was sufficietnyl disorientated or
incapacitated as to require help. If >2 SH
epsidoes between study visits, participants
were required to discontinue medication.
Cox regression models
Adjustments for age, sex, race,
ethnicity, HbA1c, NYHA class,
smoking, MI, COPD, CAD, stroke,
>50% stenosis of carotid artery, atrial
flutter/fibrillation, insulin, amputation,
diabetic neuropathy, foot ulcer, blood














Dementia: inpatient and outpatient
databases based on ICD9-CM
Hospitalisation and ED diagnoses of
hypoglycaemia using hospital/ED databases
ICD9-CM
Cox proportional hazard regression
models, adjusted for age, sex, race/
ethnicity, education, BMI, duration of




was associated with a




Dementia: hospital records indicating
an admission associated with
dementia or the use of prescribed
dementia medications
Hospital records: severe hypos requiring
admission and identified as primary or
secondary diagnosis related to overnight
hospitalisation. No information on milder
hypos not requiring admission
Cox Proportional Hazard Regression.
Adjustments for age, educational level,
race/ethnicity, and any other
covariates significantly associated with
severe hypoglycaemia or dementia in
bivariate analysis
Hypoglycaemia associated





The primary composite outcome in
the time-to-event analysis was the
first occurrence of death from
cardiovascular causes, nonfatal
myocardial infarction, or nonfatal
stroke.
Self-reported hypoglycaemia was a
secondary safety endpoint, reported using
patient diaries and transcribed into case
report form. SH defiend as requiring
assistance of another person to administer
fast-acting carbohydrates, glucagon or other
resuscitative action–reported as a medical
event of special interest.
Confirmed hypoglycaemia defined as SH or
minor hypoglycaemia (<3.1mmol/L).
Nocturnal hypoglycaemia defined as
episodes occurring between 00:01 and
05:59h. Patients asked to check blood
glucose whenever a hypoglycaemic episode
was suspected.
Cox regression to analyze time to first
MACE, CV death, non-CV death or
all-cause mortality with either SH at
any time (yes/no) as a factors or with
hypoglycaemia (SH or confirmed, yes/
no) as a time-dependent covariate.
Adjustments for randomized
treatment, basline covariates,
concomitant insulin use, HbA1c
during trial, concomitant sufonylurea/
glinide use, eGFR and event
adjudication committee-confirmed
hospitalization for heart failure during
the trial (time-dependent covariates)
MACE up to one year with
SH
aHR 1.90 (1.30–2.90)







congestive heart failure, peripheral
vascular disease.
Microvascualr: renal, ophthalmic or
neurologic manifestations with
diabetes.
ICD-9-CM codes Propensity score matching (greedy 5
to 1 method) for noncomparable
baseline characteristics
Cox proportional hazard regression
models controlling for covariates,
including baseline demographic and
illness characteristics, vital signs, prior
medication, and index drug
HR 2.00 (1.63-2.44) for
cardiovascular events, HR
1.76 (1.46, 2.11) for
microvascular
complications




ICD-9-CM codes for fall-related
events (fractures, head injuries) with
a fall being the external cause within
a two-day window.
ICD-9-CM codes McNemar tests, generalized
estimating equation (GEE)
Matching on age, gender, ethnicity
and medical service
Adjustments for social demographic
and illness characteristics, vital signs
and medication use
aOR 2.70 (1.64, 4.47) for
fall-related events in the
hypoglycaemia group
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We screened 3,175 citations in addition to the 29 papers that
were included in the previous reviews. We included 44 studies
with a total of 2,507,434 participants (3–24). The flow chart of
the study selection is shown in Figure 1.
Characteristics of the included studies and participants are
shown in Table 1. The included studies consist of 21 retrospective,
11 prospective and 12 post-hoc analyses. Geographical locations
were diverse and included North America, Canada, Asia
and Europe.
29 studies looked at patients with type 2 diabetes, whereas the
remaining studies included patients with a mix of type 1 diabetes,
type 2 diabetes, and impaired glucose tolerance/impaired fasting
glucose. Four studies focussed on oral hypoglycaemics (37–39,
46). We report details of study validity (ascertainment of adverse
outcomes, and confounding factors) in Table 2 and summarize
the key features below.
Ascertainment of Hypoglycemia
Most of the studies relied on hospital or claims data records for
severe hypoglycaemic events, ie hypoglycemia that requires help
from another person to be managed/treated. 11 studies rely on
either a history of self-reported hypoglycaemic episodes,
questionnaires, or provided participants with diaries and
glucometers (4–7, 10, 13, 16, 32, 34, 40, 45). These studies
would be considered to be lower quality because of lack of
medical documentation and high risk of recall bias.Ascertainment of Adverse Events
12 studies used pre-specified outcomes from RCTs and one non-
interventional study (5, 9–11, 13, 25, 34, 36, 40, 45, 46).
29 studies measured adverse events through database or medical
records codes, one study relied on a professional interviewer with
questionnaire (7) and one study on self-report/GP questionnaires
(4). Dementia was ascertained though a wide variety of tests.Frontiers in Endocrinology | www.frontiersin.org 16Confounding Factors
The included studies took account of potential confounding
through the use of multivariate logistic regression models. Five
studies used propensity score matching (18, 24, 34, 43, 47).META-ANALYSIS
Association Between Hypoglycemia and
Macro- and Microvascular Disease and
Cardiovascular Death
19 studies confirmed a significant association between
hypoglycemia and macrovascular complications (3, 4, 10, 11,
14, 16, 17, 18, 20, 23, 26, 28, 34, 36, 38, 40, 43, 45, 46). The pooled
odds ratio was 1.81 (95% CI 1.70–1.94). There was low
heterogeneity (I2 = 6%).
Similarly, two studies confirmed a significant association
between hypoglycemia and microvascular complications (43,
46). The microvascular complications covered in the study
were nephropathy or retinopathy (46) and a composite
endpoint of several complications (43). The pooled odds ratio
was 1.77 (95% CI 1.49–2.10) with no evidence of heterogeneity
(I2 = 0%) (Figure 2).
Six studies reported on cardiovascular death and confirmed
a significant association between hypoglycaemia and
cardiovascular death. The pooled odds ratio was 2.11 (95% CI
1.55–2.87) with evidence of moderate heterogeneity (I2 = 50%)
(6, 10, 13, 34, 40, 46).Association Between Hypoglycemia and
Falls or Fractures
Six studies reported on falls (3, 7, 22, 30, 39, 44) with a pooled
odds ratio of 1.78 (95% CI 1.44–2.21) and substantial
heterogeneity (I2 = 87%).TABLE 2 | Continued
Study ID Method of diagnosing each type
of adverse event
Method of diagnosing or determining that
patients had hypoglycaemia
Statistical adjustments for




First major macrovascular event =
death from cardiovascular cause,
non-fatal MI, non-fatal stroke
First major microvascular event =
new or worsening nephropathy or
retinopathy
Secondary outcomes = death from
any cause and death from a
cardiovascular event
Independent adjudication by blinded
committee
Blood glucose level <2.8 mmol/L or typical
symptoms/signs without other apparent
cause. Those with transient neurological
dysfunction who required help from 3rd party
were considered to have severe
hypoglycaemia. Minor hypoglycaemia if




Baseline: sex, duration of diabetes,




Time dependent covariates during
follow-up: age, HbA1c, body mass
index, creatinine, urine albumin to
creatinine ratio, systolic blood
pressure, diabetes and blood
pressure drugs.
HR 2.88 (2.01, 4.12)
major macrovascular
events, HR 1.81 (1.19,
2.74) major microvascular
events, HR 2.68 (1.72,
4.19) death from
cardiovascular cause, HR
2.69 (1.97, 3.67) death
from any causeMarch 2021 | VOR, Odds ratio; HR, Hazard ratio; 95% CI, 95% Confidence Interval; T2DM,Type 2 diabetes mellitus; HbA1C,glycated haemoglobin; CKD, chronic kidney disease; DPP-4,dipetidyl-
peptidase-4; SU, Sulfonylureas; MI, myocardial infarction; AF, atrial fibrillation; CVD, cardiovascular disease; HES, Hospital Episode Statistic; CPRD, Clinical Practice Research Datalink
database; TUG, Timed Up and Go Test; GDS-15,Geriatric Depression Scale; CCI, Charlson comorbidity index; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; SH, severe
hypoglycaemia; ACEi, angiotension-converting enzyme inhibitor; ARB, angiotension receptor blocker; TIA, transient ischemic attack; MMSE, Mini-Mental State Examination; eGFR,
estimated glomerular filtration rate.olume 12 | Article 571568
Mattishent and Loke Harmful Effects of Low Blood SugarsSix studies reported on fractures with a pooled odds ratio of
1.68 (95% CI 1.37–2.07) and considerable heterogeneity (I2 =
91%) (3, 19, 20, 22, 35, 37) (Figure 3).
Association Between Hypoglycemia and
Mortality
18 studies reported on overall mortality confirming a significant
association between hypoglycemia and mortality with a pooled
odds ratio of 2.02 (95% CI 1.75–2.32) and substantial
heterogeneity (I2 = 86%) (3, 5, 6, 10, 12, 13, 18, 23, 25, 26, 31,
32, 34, 36, 40, 43, 45, 46) (Figure 4). Despite the heterogeneity, the
direction of association was consistent across all the studies in the
Forest plot. Two studies did not find a statistically significant
association between hypoglycemia and mortality (13, 43).Frontiers in Endocrinology | www.frontiersin.org 17We also conducted a sensitivity analysis for mortality hazard
ratios (HRs) at different durations of follow-up, which three
studies addressed (Figure 5). The HR is greatest early on
[pooled HR 4.08 (95% CI 3.44–4.85) at 90-days follow-up]
and diminishes with time after the hypoglycaemic episode
[pooled HR 2.43 (95% CI 2.17–2.71) at 365-days follow-up]
(3, 36, 45).
Association between hypoglycemia and
dementia
9 studies confirmed a significant association between
hypoglycemia and dementia (8, 9, 15, 24, 27, 33, 41, 42) with a
pooled odds ratio of 1.50 (95% CI 1.29–1.74). There was
substantial heterogeneity with I2 = 85% (Figure 6).FIGURE 1 | PRISMA flow chart.March 2021 | Volume 12 | Article 571568
Mattishent and Loke Harmful Effects of Low Blood SugarsFIGURE 2 | Meta-analysis of association between hypoglycemia and macro- and microvascular disease and cardiovascular death.FIGURE 3 | Meta-analysis of association between hypoglycemia and falls and fractures.Frontiers in Endocrinology | www.frontiersin.org March 2021 | Volume 12 | Article 57156818
Mattishent and Loke Harmful Effects of Low Blood SugarsSensitivity analysis – restriction to studies
with patients’ mean age ≥65 years
As there is no consensus on the age-threshold for ‘older’ patients,
we conducted a sensitivity analysis where we excluded studies in
younger patients (mean age< 65 years). The pooled odds ratiosFrontiers in Endocrinology | www.frontiersin.org 19were modestly increased when restricted to older patients, thus
suggesting the possibility of greater harm associated with
hypoglycemia with older age: Macrovascular events OR 1.88
(95% CI 1.72–2.07), Falls OR 1.98 (95% CI 1.80–2.19), and Death
OR 2.25 (95% CI 1.78–2.83).FIGURE 4 | Meta-analysis of association between hypoglycemia and mortality.FIGURE 5 | Sensitivity analysis: Mortality HRs at different durations of follow-up.March 2021 | Volume 12 | Article 571568
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Reporting
We constructed a funnel plot for the meta-analysis on the
association between hypoglycemia and vascular events, as more
than ten studies were included in the analysis (see Supplemental
Figure 1). On visual inspection of the funnel plot there are very
few small studies that contributed to the meta-analysis, and it is
difficult to judge presence or absence of asymmetry. As such, we
cannot rule out the possibility of selective reporting or
publication bias.DISCUSSION
This updated meta-analysis incorporated 23 new studies to the
previously published meta-analyses on the association between
hypoglycemia and adverse events in older people with diabetes.
The total of 44 observational studies (involving over 2.5 million
participants) confirms the danger of hypoglycemia in older
people with diabetes, which is consistent with the previously
published reviews.
Our meta-analyses demonstrated significant associations
between hypoglycemia and death, dementia, macrovascular
and microvascular complications, cardiovascular death, and
falls and fractures. In our previous work, we were unable to
report on cardiovascular death due to lack of data, but we have
now been able to perform this meta-analysis with six studies (6
10, 13, 34, 40, 46).
In addition, our new sensitivity analysis of mortality HRs at
different times of follow-up also shows that the HR for death is
greatest early on and diminishes with longer follow-up
duration. This suggests that the association between
hypoglycaemic episodes and death is not just due to baseline
confounding. If that were the case, we would not expect to see
diminishing hazard ratios with longer intervals of time after the
hypoglycaemic episode.Frontiers in Endocrinology | www.frontiersin.org 20The collated evidence regarding serious harm supports our
argument that we should prioritize the avoidance of hypoglycemia
in this vulnerable group of patients.
An international consensus on clinical targets for continuous
glucose monitoring data was published in June 2019, highlighted
that older adults with diabetes should spend less than 15 minutes
per day in the hypoglycaemic range (<3.9mmol/L) (48). This is of
particular significance, as hypoglycaemic episodes are often
missed in older people with diabetes (49).
We are aware of studies that have identified potential links
between hypoglycemia and cardiac arrhythmias (50, 51), which
could account in part for the findings of increased risk of myocardial
infarction, stroke, falls and death following hypoglycemia.
Regarding cognitive adverse effects, a recent study found that
hypoglycemia was associated with smaller total brain volume on
MRI (27). Furthermore, Gibas et al. put forward the theory of
“brain starvation” in patients with type 2 diabetes, due to
concurrent hyperinsulinemia and relative hypoglycemia due to
insulin resistance resulting in apoptosis of healthy neurons from
catabolic degeneration (52). Radiological studies in patient who
had suffered profound hypoglycemia have shown that neurons in
the hippocampal and temporal areas, cerebral cortex, substantia
nigra, and basal ganglia are particularly sensitive to hypoglycemia
(53). Cognitive decline may in turn pre-dispose older frail people
to falls, fractures and death following hypoglycemia.
Limitations
We cannot prove causality due to the observational nature of the
studies. Although we identified heterogeneity in some of the
meta-analyses, the direction of the effect was consistent amongst
the studies. Factors which could be influencing heterogeneity
include different classes of medications, different geographical
locations, different study designs and the accuracy of
ascertainment of hypoglycaemic episodes and adverse events.
We considered summarizing the evidence using GRADE,
however, this tool is mainly designed for recommendations on
healthcare intervention and not for etiology and prognostic studies.FIGURE 6 | Meta-analysis of association between hypoglycemia and dementia.March 2021 | Volume 12 | Article 571568
Mattishent and Loke Harmful Effects of Low Blood SugarsThe two main areas within GRADE that cannot be applied here are
‘measure of indirectness’ and ‘estimation of absolute effect size’.
Regarding publication bias, if null or negative findings are not
fully reported, this may result in inflated estimates of association in
the meta-analyses. However, there were very few small studies in
the funnel plot analysis we performed in relation to cardiovascular
events, and so it is not possible for us to rule out bias from non-
publication of small studies.CONCLUSIONS
Our updated review provides a strong evidence base to support
and strengthen our argument about the importance of adopting a
hypoglycemia minimization strategy. Further work has to be
carried out in older people with diabetes to establish effective
hypoglycemia minimization strategies through better
monitoring via continuous glucose monitoring coupled withFrontiers in Endocrinology | www.frontiersin.org 21de-intensification of management regimes, rather than the
pursuit of specific HbA1c targets.AUTHOR CONTRIBUTIONS
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